Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q2

4583.TEDINET S100RN56
Period2023-01-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed

Amended by S100S9VE (2023-11-13).

Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥359m2023-01-01 → 2023-06-30StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥278m2022-01-01 → 2022-06-30StandaloneNet sales
Operating income−¥659m2023-01-01 → 2023-06-30StandaloneOperating income
Operating income−¥779m2022-01-01 → 2022-06-30StandaloneOperating income
Ordinary income−¥662m2023-01-01 → 2023-06-30StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥769m2022-01-01 → 2022-06-30StandaloneOrdinary income
Profit before tax−¥661m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Profit before tax−¥769m2022-01-01 → 2022-06-30StandaloneIncome before income taxes
Net income−¥664m2023-01-01 → 2023-06-30StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥771m2022-01-01 → 2022-06-30StandaloneProfit loss
Total assets¥1.7bnat 2023-06-30StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥1.9bnat 2022-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥541mat 2023-06-30StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2023-06-30StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2022-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2023-06-30StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥1.2bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2022-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥595m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥660m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥82,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥113m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥341m2022-01-01 → 2022-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-13.72023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-92023-04-01 → 2023-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-18.172022-01-01 → 2022-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.532022-04-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio67.2%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio75.3%at 2022-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued48,503,800at 2023-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued43,057,600at 2022-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥266m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥602m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-06-30¥209m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30−¥393m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥239m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-06-30−¥691m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-06-30¥278m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-06-30¥151m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥278m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥540m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 444
ItemContextValueUnit
Advances receivedCurrentQuarterInstant_NonConsolidatedMember22100000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember4835000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember5534000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6351000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember6922000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember370455000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember486440000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54268000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54480000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54268000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54480000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember424724000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember540921000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2097017000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember2106252000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3696798000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember3706032000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-4016331000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-4679987000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1777192000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1132005000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember13554000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember12624000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1790746000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1144629000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1685551000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember278211000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember358889000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember127082000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember150211000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember151129000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember208677000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember690981000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember601900000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember239364000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember266026000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember930345000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember867926000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-779216000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-659249000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember11000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember10000JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember16000000JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember－JPY
Other noiPrior1YTDDuration_NonConsolidatedMember205000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember414000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember16216000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-06-30pass